EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetics modeling of albendazole and its active metabolite, albendazole sulfoxide in mass drug administration against lymphatic filariasis

Abdullah Alshehri iD, Christopher L King, Daryl J Murry iD

Antimicrobial Agents and Chemotherapy · 04.11.2026 · 70 (11)

DOI: 10.1128/aac.00562-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.11.2026. Verfasst von Abdullah Alshehri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia. Hauptthemen laut MEDLINE: Albendazole, Elephantiasis, Filarial, Filaricides. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Albendazole (ALB), a benzimidazole antiparasitic, is widely used in mass drug administration (MDA) campaigns against lymphatic filariasis (LF). It is rapidly metabolized to its active form, albendazole sulfoxide (ALB-OX), which exhibits considerable interindividual variability (IIV) in pharmacokinetics (PK). This variation may affect ALB efficacy in MDA programs. We developed a population pharmacokinetic (PopPK) model characterizing ALB and ALB-OX exposure and identifying demographic and clinical covariates contributing to IIV in patients with LF and healthy individuals. Plasma concentration-time data were pooled from three clinical studies involving ALB co-administered with ivermectin and diethylcarbamazine. Nonlinear mixed-effects modeling was conducted using Phoenix NLME. Covariate effects (e.g., sex, age, infection status) were assessed, and model validation employed visual predictive checks and bootstrapping. Simulations explored covariate impact on exposure. A joint two-compartment model with transit absorption for ALB and pre-systemic ALB-OX formation best described the data. Sex significantly influenced ALB-OX clearance and volume of distribution, with males exhibiting higher clearance and lower exposure. Body weight, age, and LF infection status did not significantly affect PK parameters. Simulations confirmed 33% lower ALB-OX levels in males compared to females following a 400 mg oral ALB dose. This is the first PopPK model of ALB and ALB-OX in LF-endemic populations. It highlights sex as a key covariate explaining IIV in ALB-OX exposure, with implications for optimized dosing in MDA programs. Further studies incorporating pharmacogenetics and pediatric data are warranted. This study is registered with ClinicalTrials.gov as NCT04410406 , NCT02845713 , and NCT03664063 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbendazoleElephantiasis, FilarialFilaricidesAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultDiethylcarbamazineMass Drug AdministrationClinical Trials as Topic

Stichwörter der Autor:innen

albendazolealbendazole sulfoxidebancroftian filariasislymphatic filariasismass drug administrationpopulation pharmacokinetics

Substanzen

Albendazolealbendazole sulfoxideDiethylcarbamazineFilaricides

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
  • Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
  • Veterans Affairs Research Service, VA Medical Center, Cleveland, Ohio, USA.
  • Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA.

ORCID-Profile: Abdullah Alshehri, Daryl J Murry

Förderung

  • Bill and Melinda Gates Foundation

Zitieren

APA

Alshehri, A., King, C. L., & Murry, D. J. (2026). Population pharmacokinetics modeling of albendazole and its active metabolite, albendazole sulfoxide in mass drug administration against lymphatic filariasis. Antimicrobial Agents and Chemotherapy, 70(11). https://doi.org/10.1128/aac.00562-26

Vancouver

Alshehri A, King CL, Murry DJ. Population pharmacokinetics modeling of albendazole and its active metabolite, albendazole sulfoxide in mass drug administration against lymphatic filariasis. Antimicrobial Agents and Chemotherapy. 2026;70(11). doi:10.1128/aac.00562-26

BibTeX
@article{Alshehri2026,
  author = {Alshehri, Abdullah and King, Christopher L and Murry, Daryl J},
  title = {Population pharmacokinetics modeling of albendazole and its active metabolite, albendazole sulfoxide in mass drug administration against lymphatic filariasis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {11},
  doi = {10.1128/aac.00562-26}
}
Kostenlos starten →